As researchers continue to explore how physical activity affects the human body, an increasingly active branch of biomedical research is focusing on molecular pathways that help muscles adapt to exercise. One emerging strategy is to develop compounds designed to activate pathways related to aerobic metabolism, mitochondrial function, and energy utilization.
Among these compounds, SLU-PP-915 has attracted significant attention because of its activity on estrogen-related receptors (ERRs). ERRs are orphan nuclear receptors that play a crucial role in regulating cellular energy metabolism. Preclinical studies have shown that activating these receptors may recreate some molecular responses typically associated with aerobic exercise, opening new opportunities for research into metabolism and muscle physiology.
However, researchers emphasize that the field remains preclinical. Current research on SLU-PP-915 comes mainly from laboratory and animal experiments and is primarily used for research.
Why is simulated exercise research attracting so much attention?
The effects of exercise extend far beyond muscle strength or cardiovascular health. Regular aerobic exercise can influence mitochondrial activity, glucose utilization, fatty acid oxidation, energy expenditure, and gene expression.
A key regulatory system involved in these processes is the estrogen-associated receptor family, primarily composed of ERRα, ERRβ, and ERRγ. Despite their similar names, ERRs are distinctly different from traditional estrogen receptors. As transcriptional regulators, they help control genes involved in mitochondrial metabolism, oxidative phosphorylation, fatty acid utilization, and the tricarboxylic acid cycle.
This makes the ERR signaling pathway particularly important for researchers studying how cells respond to increased energy demands.
During aerobic exercise, skeletal muscle requires more energy. Mitochondria respond by increasing oxidative metabolism and regulating the expression of genes involved in energy production. Therefore, researchers are exploring whether activating certain same molecular pathways through drugs can provide a useful experimental model for understanding exercise adaptation. This concept is often called the "exercise mimicry" approach. Importantly, exercise mimicry does not actually replace physical activity. Instead, it tests whether activating specific molecular pathways can reproduce exercise-associated cellular or metabolic responses.
What metabolic information can SLU-PP-915 reveal to researchers?
SLU-PP-915 is a synthetic small molecule developed as a "pan-ERR agonist," meaning it can activate ERRα, ERRβ, and ERRγ. Researchers published its development in a 2023 issue of Medicinal Chemistry Research, where they identified the compound as part of a novel family of compounds targeting the ERR signaling pathway.
The compound has the molecular formula C17H13BFNO3S, a molecular weight of approximately 341.2 g/mol, and the CAS number 2285432-92-8. PubChem identifies it as a small molecule, not a peptide. Early pharmacological studies found that SLU-PP-915 increases the expression of multiple genes associated with the ERR signaling pathway, including those related to mitochondrial and metabolic regulation. Researchers reported changes in the expression of PGC-1α, PDK4, LDHA, and DDIT4, indicating that the compound can affect transcriptional programs related to energy metabolism. Researchers also reported that SLU-PP-915 has oral bioavailability and enhances aerobic exercise capacity in mice. The study also found that the compound could induce Ddit4 expression, a gene associated with acute aerobic exercise, and that combining the compound with exercise training further enhanced the responses of several exercise- and mitochondrial-related genes. These findings help explain why the ERR signaling pathway has become a hot topic in metabolic research. Researchers are no longer focusing solely on single metabolic enzymes, but rather on whether ERR activation can affect a broader network of genes involved in cellular energy management.
Could this research lead to new approaches for treating metabolic diseases?
The potential implications of exercise simulation studies extend far beyond athletic performance. Researchers are interested in whether regulating metabolic pathways can ultimately help study diseases associated with mitochondrial dysfunction, altered energy metabolism, or declining physical performance.
Preclinical studies of ERR agonists have explored obesity, metabolic dysfunction, cardiovascular disease, muscle diseases, and age-related mitochondrial changes.
A recent systematic review also examined pan-ERR agonists (such as SLU-PP-332 and SLU-PP-915) as potential tools for exercise simulation studies. The review reported evidence from animal and cellular studies involving energy metabolism, muscle function, mitochondrial activity, and metabolic disease models. However, the review noted that clinical studies are still needed to determine their efficacy and safety in humans.
This distinction is crucial. Results observed in mice or isolated cells do not directly translate to human health outcomes. Differences in metabolism, dosage, pharmacokinetics, long-term exposure, and biological responses can significantly affect compound effects in humans. Interest is also growing in the analytical and regulatory implications of ERR agonists. A 2026 study using human liver tissue and analytical mass spectrometry investigated the metabolism of SLU-PP-915 and SLU-PP-332, reflecting the scientific community's increasing interest in the metabolism and detection methods of these compounds.
Currently, SLU-PP-915's primary value lies in its role as a research tool for studying the biology of endogenous receptors (ERRs) and exercise-related metabolic signaling. It can activate multiple ERR subtypes, providing researchers with opportunities to investigate how these receptors affect mitochondrial and skeletal muscle pathways. As research progresses, scientists need to determine whether the metabolic changes observed in preclinical models can be safely and effectively reproduced in humans. Future research may also clarify which aspects of exercise-related biology ERR activation can influence and which depend on the broader physiological effects of physical activity.
The growing interest in simulated exercise research ultimately reflects a broader shift in metabolic science: researchers are no longer focusing solely on individual molecules or enzymes, but increasingly on the interconnected signaling networks that coordinate energy production, mitochondrial function, and muscle adaptation.
Therefore, SLU-PP-915 represents an emerging research approach whose current scientific significance lies in helping researchers explore how ERR signaling pathways regulate metabolism and how the pharmacological activation of these pathways can reproduce certain molecular characteristics of aerobic exercise. Further laboratory, animal, and ultimately clinical studies are needed to determine the broader implications of this strategy.